News
BJDX
0.6499
+17.95%
0.0989
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results. Tesla posted weaker-than-expected earnings and sales results for its first quarter on Tuesday. The electric vehicle giant also announced plans to speed up the launch of new models. Chicken Soup for the Soul Entertainment shares gained 49.4% in pre- market trading.
Benzinga · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Chicken Soup for the Soul (NASDAQ:CSSE) stock is rocketing more than 68% alongside heavy pre-market trading. Tesla’s stock is surging close to 24% following its latest earnings report. Earnings reports, a reverse stock split and more are the biggest pre- market stock movers.
Investorplace · 2d ago
Weekly Report: what happened at BJDX last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at BJDX last week (0408-0412)?
Weekly Report · 04/15 11:57
Weekly Report: what happened at BJDX last week (0401-0405)?
Weekly Report · 04/08 12:03
Bluejay Diagnostics Announces CFO Change and Stockholders’ Meeting Date
TipRanks · 04/02 21:23
Weekly Report: what happened at BJDX last week (0325-0329)?
Weekly Report · 04/01 12:00
Bluejay Diagnostics Q4 EPS $(1.78) Misses $(0.68) Estimate
Benzinga · 03/29 04:56
BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023
Bluejay Diagnostics reported earnings per share of -$1.78 for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -68 cents. Bluejay Diagnostic just reported results.
Investorplace · 03/29 03:53
Weekly Report: what happened at BJDX last week (0318-0322)?
Weekly Report · 03/25 12:03
Weekly Report: what happened at BJDX last week (0311-0315)?
Weekly Report · 03/18 12:01
Weekly Report: what happened at BJDX last week (0304-0308)?
Weekly Report · 03/11 11:57
Weekly Report: what happened at BJDX last week (0226-0301)?
Weekly Report · 03/04 12:00
Weekly Report: what happened at BJDX last week (0219-0223)?
Weekly Report · 02/26 12:18
12 Health Care Stocks Moving In Friday's After-Market Session
Ocean Biomedical (NASDAQ:OCEA) stock rose 37.6% to $2.16 during Friday's after-market session. The company's market cap stands at $73.6 million. NeuBase Therapeutics and Virax Biolabs Group also moved upwards. Losers include Telesis Bio and Celularity.
Benzinga · 02/23 21:31
Weekly Report: what happened at BJDX last week (0212-0216)?
Weekly Report · 02/19 12:21
Weekly Report: what happened at BJDX last week (0205-0209)?
Weekly Report · 02/12 12:06
Weekly Report: what happened at BJDX last week (0129-0202)?
Weekly Report · 02/05 12:19
Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
ZIM Integrated Shipping Services Ltd. Shares rose sharply in today's pre-market trading. Jefferies upgraded the stock from Hold to Buy and raised its price target. NovaBay Pharmaceuticals, Inc. Shares jumped 71.3% to $0.2810 in pre- market trading.
Benzinga · 01/29 12:56
Weekly Report: what happened at BJDX last week (0122-0126)?
Weekly Report · 01/29 12:02
More
Webull provides a variety of real-time BJDX stock news. You can receive the latest news about Bluejay Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About BJDX
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.